Biologics

Here are five trends on the evolution of spinal biologics and what to expect in the future.

Research presented at the Society for Minimally Invasive Spine Surgery Annual Forum in 2018 compares static and expandable interbody devices for minimally invasive transforaminal lumbar interbody fusion.

Spine surgery is shifting away from traditional devices and toward biologics, a material that attracts cells to increase bone formation in spinal fusion procedures, according to Jeffrey Wang, MD, who is the University of California-Los Angeles spine service chief and…

A new study published in The Spine Journal examines fusion rate for standalone anterior lumbar interbody fusions.

New York Attorney General Letitia James is suing New York City-based Park Avenue Stem Cell alleging the clinic performed unproven and rogue procedures on patients, the New York Times reports.

A new study published in the Journal of Neurosurgery: Spine examines the role of BMP use during spinal deformity cases.

The Journal of Neurosurgery published an article outlining "awake spinal fusion" using the endoscopic transforaminal lumbar interbody fusion technique without general anesthesia.

InVivo Therapeutics reported raising net proceeds of $16.5 million in 2018 and implemented significant cost savings measures last year.

Bioventus launched Osteoamp Select Fibers for use with its bone graft substitutes for spine, foot, ankle orthopedic and trauma surgeons.

Using the bone morphogenetic protein rhBMP-2 in the disc space for minimally invasive transforaminal lumbar interbody fusion led to a 97.9 percent fusion rate, according to a study in Clinical Spine Surgery.